US EditionLatham and Covington Advise on Novartis’s Acquisition of Regulus
Summary by Law Street Media
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Latham and Covington Advise on Novartis’s Acquisition of Regulus
Novartis announced plans to acquire Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company developing medicines targeting microRNAs, for $800 million. The all cash deal includes a contingent value right providing for an additional payment of $7.00 per share to Regulus shareholders, contingent upon the achievement of a milestone with respect to regulatory approval of the company’s farabursen product, which aims to treat autosomal do
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
